Why did Danaher (DHR) stock move recently?

On 9/1/2026, Danaher moved -3.1% — Danaher fell 3.1% as investors continued digesting its Q2 earnings, where the company beat revenue/EPS but narrowed full-year core revenue growth guidance to 3-4% amid ~$100M+ in bioprocessing shipment delays into 2027, alongside the announced October CEO transition and recent executive share sales. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Danaher (DHR) overvalued or fairly valued?

MarketChacha shows Danaher's valuation in context — a trailing P/E of about 44.0, a forward P/E of about 22.7, a price-to-book of about 2.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Danaher's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.65×) from reported figures — education, not a rating.

What is Danaher's revenue?

Danaher reported revenue of $24.6B for FY2025, with net profit of $3.6B, per official filings.

What is the share price of Danaher (DHR)?

Danaher last traded at $207.66 (-1.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Danaher

DHR · NYSE · Life Sciences · United States

Snapshot

TickerDHR

ExchangeNYSE

SectorLife Sciences

IndustryDiagnostics & Research

CountryUnited States

Employees58,000

HeadquartersWashington, United States

Websitewww.danaher.com

Filings tracked19

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Who owns it

Insiders11.0%
Institutions84.4%
Public & other4.6%

2,864 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.7.84%
Vanguard Capital Management LLC5.89%
FMR, LLC4.20%
State Street Corporation4.05%
Wellington Management Group, LLP2.32%
Capital International Investors2.21%
Geode Capital Management, LLC2.03%
Vanguard Portfolio Management LLC2.02%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 5.2 points over the period — profitability is trending down.

Cash conversion1.65×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend19.9% → 14.7%

Margin has compressed by about 5.2 points over the period — profitability is trending down.

Return on equity6.9%

Latest ROE of 6.9% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 1% · PAT -13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $7.6B · EPS 2.58

Est. earnings growth +15.8%

Next fiscal year

Rev $28.5B · EPS 9.30

Est. earnings growth +9.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$24.6B

Net margin

14.7%

ROE

6.9%

Revenue CAGR (2y)

+1.4%

Profit CAGR (2y)

-12.9%

EPS (FY2025)

5.05

Net profit (FY2025)

$3.6B

Ask MarketChacha about DHR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 1, 2026
Danaher fell 3.1% as investors continued digesting its Q2 earnings, where the company beat revenue/EPS but narrowed full-year core revenue growth guidance to 3-4% amid ~$100M+ in bioprocessing shipment delays into 2027, alongside the announced October CEO transition and recent executive share sales.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Jul 23, 2026
Danaher shares rebounded after a sharp ~11% post-Q2 earnings selloff the prior day, with buying interest returning amid commentary on strength in cell culture markets and normalizing bioprocessing demand despite some analyst target cuts.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium
Jul 21, 2026
Danaher beat Q2 EPS estimates and raised full-year adjusted EPS guidance but lowered its 2026 core revenue growth outlook to 3-4% (from a prior higher range) due to weaker bioprocessing/biotech revenue from customer project timing and softer respiratory testing, prompting the sharp drop despite the headline beat.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about DHR

Why did Danaher (DHR) tank ~14% on a day it beat AND raised EPS?c/usmarkets · 7/22/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$24.6B	$3.6B	5.05	14.7%	6.9%
FY2024	$23.9B	$3.9B	5.29	16.3%	7.9%
FY2023	$23.9B	$4.8B	6.38	19.9%	8.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$6.3B	$870.0M	1.23	13.9%
2026Q1	$6.0B	$1.0B	1.45	17.3%
2025Q3	$6.1B	$908.0M	1.27	15.0%
2025Q2	$5.9B	$555.0M	0.77	9.3%
2025Q1	$5.7B	$954.0M	1.32	16.6%
2024Q3	$5.8B	$818.0M	1.12	14.1%
2024Q2	$5.7B	$907.0M	1.22	15.8%
2024Q1	$5.8B	$1.1B	1.45	18.8%
2023Q4	$6.4B	—	1.45	—
2023Q3	$5.6B	$1.1B	1.51	20.1%
2023Q2	$5.9B	$1.1B	1.49	18.7%
2023Q1	$5.9B	$1.4B	1.94	24.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Other events, Exhibits
SEC8/3/2026material
10-Q filing
SEC7/21/2026
8-K — Results of operations, Exhibits
SEC7/21/2026material
8-K — Material financial obligation, Other events
SEC6/3/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/7/2026material
8-K — Material agreement, Other events, Exhibits
SEC4/29/2026material
10-Q filing
SEC4/21/2026
8-K — Results of operations, Exhibits
SEC4/21/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC4/17/2026material
10-K filing
SEC2/24/2026
8-K — Other events, Exhibits
SEC2/17/2026material
8-K — Executive/director change, Exhibits
SEC2/10/2026material
8-K — Results of operations, Exhibits
SEC1/28/2026material
8-K — Results of operations, Exhibits
SEC1/12/2026material

2025

8-K — Executive/director change, Exhibits
SEC11/6/2025material
8-K — Results of operations, Exhibits
SEC10/21/2025material
10-Q filing
SEC10/21/2025
8-K — Bylaw/charter change, Other events, Exhibits
SEC9/10/2025material
8-K — Executive/director change, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.